Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2011-08-09
2011-08-09
Swartz, Rodney P. (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S009100, C424S009200, C424S184100, C424S234100, C435S004000, C435S007100, C435S007200, C530S300000, C530S350000
Reexamination Certificate
active
07993650
ABSTRACT:
A polypeptide is provided, which has a binding affinity for HER2 and which is related to a domain of staphylococcal protein A (SPA) in that the sequence of the polypeptide corresponds to the sequence of the SPA domain having from 1 to about 20 substitution mutations. Nucleic acid encoding the polypeptide, as well as expression vector and host cell for expressing the nucleic acid, are also provided. Also provided is the use of such a polypeptide as a medicament, and as a targeting agent for directing substances conjugated thereto to cells overexpressing HER2. Methods, and kits for performing the methods, are also provided, which methods and kits rely on the binding of the polypeptide to HER2.
REFERENCES:
patent: 2006/0210579 (2006-09-01), Telford et al.
patent: WO 89/06692 (1989-07-01), None
patent: WO 95/19374 (1995-07-01), None
patent: WO 00/23580 (2000-04-01), None
patent: WO 00/63243 (2000-10-01), None
patent: WO 01/01748 (2001-01-01), None
patent: WO 01/77342 (2001-10-01), None
patent: WO 02/08263 (2002-01-01), None
Uhlen, M. et al. Journal of Biological Chemistry, vol. 259, No. 3, pp. 1695-1702, 1984.
Cedergren, L., et al., “Mutational analysis of the interaction between staphylococcal protein A and human IgG,” 6123 Protein Engineering, vol. 6, No. 4., 1993, pp. 441-448.
Nord, K., et al., “A combinatorial library of an α-helical bacterial receptor domain,” Protein Engineering, vol. 8, No. 6, 1995, pp. 601-608.
Wikman, M. et al., “Selection and characterization of HER2
eu-binding affibody ligands”, Protein Engineering, Design & Selection, vol. 17, No. 5, pp. 455-462 (Jun. 2004).
Nord, Karin et al., “Binding proteins selected from combinatorial libraries of an α-helical bacterial recptor domain”, Nature Biotechnology, vol. 15, pp. 772-777 (Aug. 1997).
Gunneriusson, E. et al., “Affinity maturation of a Taq DNA polymerase specific affibody by helix shuffling”, Protein Engineering, vol. 12, No. 10, pp. 873-878 (1999).
Slamon, M.D., Ph.D., Dennis J. et al., “Use of Chemotherapy Plus a Monoclonal Antibody Against HER2 for Metastatic Breast Cancer that Overexpresses HER2”, The New England Journal of Medicine, vol. 344, No. 11, pp. 783-792 (Mar. 15, 2001).
Carlsson Jörgen
Eriksson Tove
Gunneriusson Elin
Nilsson Fredrik
Ståhl Stefan
Affibody AB
Garabedian Todd E.
Swartz Rodney P.
Wiggin and Dana LLP
LandOfFree
Polypeptides having binding affinity for HER2 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polypeptides having binding affinity for HER2, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polypeptides having binding affinity for HER2 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2739864